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Aims Vertebrate heart development requires the complex morphogenesis of a linear tube to form the mature organ, a
process essential for correct cardiac form and function, requiring coordination of embryonic laterality, cardiac
growth, and regionalized cellular changes. While previous studies have demonstrated broad requirements for extra-
cellular matrix (ECM) components in cardiac morphogenesis, we hypothesized that ECM regionalization may fine




Using live in vivo light sheet imaging of zebrafish embryos, we describe a left-sided expansion of the ECM between
the myocardium and endocardium prior to the onset of heart looping and chamber ballooning. Analysis using an
ECM sensor revealed the cardiac ECM is further regionalized along the atrioventricular axis. Spatial transcriptomic
analysis of gene expression in the heart tube identified candidate genes that may drive ECM expansion. This ap-
proach identified regionalized expression of hapln1a, encoding an ECM cross-linking protein. Validation of transcrip-
tomic data by in situ hybridization confirmed regionalized hapln1a expression in the heart, with highest levels of ex-
pression in the future atrium and on the left side of the tube, overlapping with the observed ECM expansion.
Analysis of CRISPR-Cas9-generated hapln1a mutants revealed a reduction in atrial size and reduced chamber bal-
looning. Loss-of-function analysis demonstrated that ECM expansion is dependent upon Hapln1a, together support-
ing a role for Hapln1a in regionalized ECM modulation and cardiac morphogenesis. Analysis of hapln1a expression
in zebrafish mutants with randomized or absent embryonic left–right asymmetry revealed that laterality cues posi-
tion hapln1a-expressing cells asymmetrically in the left side of the heart tube.
....................................................................................................................................................................................................
Conclusion We identify a regionalized ECM expansion in the heart tube which promotes correct heart development, and pro-
pose a novel model whereby embryonic laterality cues orient the axis of ECM asymmetry in the heart, suggesting
these two pathways interact to promote robust cardiac morphogenesis.
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1. Introduction
Congenital heart defects are the most common human birth abnormal-
ity, with an incidence of approximately 1% of live births.1 These struc-
tural malformations arise due to abnormal morphogenesis and
maturation of the heart during embryonic development. A key stage in
cardiac development occurs when the heart transitions from a linear
tube to an asymmetric organ, a process including initial looping morpho-
genesis of the tube and subsequent ballooning of the cardiac chambers.
Correct cardiac morphogenesis is vital for ensuring normal blood flow
through the heart, proper chamber and vessel alignment, valve formation
and septation, and is therefore a tightly controlled process requiring in-
tricate coordination of heart-extrinsic signalling cues, cardiac growth,
and tissue-intrinsic changes in cell shape.2
The requirement for embryonic left–right signalling pathways in pro-
moting directionality of heart morphogenesis is well established, with
asymmetric Nodal signalling playing a key role in driving rightward loop-
ing of the linear heart tube in multiple organisms.3–6However, while em-
bryos with defective asymmetric Nodal signalling display disrupted
directionality of heart looping, the heart still undergoes looping morpho-
genesis.5–7 This indicates that while extrinsic asymmetric cues provide di-
rectional information to the heart, regionalized intrinsic signals may help
to promote morphogenesis. How the interplay of both extrinsic and
intrinsic regionalized signalling and cell behaviours ensures the coordina-
tion of directionality and morphogenesis required to orient and shape
the heart remains unknown.
The developing heart tube is composed of two tissue layers: an outer
tube of myocardium surrounding an inner layer of specialized endothelial
cells (endocardium). These two layers are separated by an extracellular
matrix (ECM), termed the cardiac jelly. The ECM consists of collagens,
glycosaminoglycans, and glycoproteins and plays a pivotal role in provid-
ing mechanical cues and modulating extracellular signalling in the heart
during cardiac development.8 Classic embryological experiments dem-
onstrated that the cardiac jelly is important for heart morphogenesis9
while more recent studies have begun to identify specific ECM constitu-
ents with distinct roles in heart development.10–16 Hyaluronic acid (HA)
is a glycosaminoglycan with conserved roles in heart tube formation, car-
diac morphogenesis and atrioventricular valve development,10,17,18 sug-
gesting multiple requirements for HA at various stages during cardiac
development. While broad disruption of the cardiac ECM has profound
effects on heart morphology,17,19 it is likely that the ECM plays distinct
functions in regulating regionalized morphogenesis of the heart tube.
In this study, we demonstrate that the cardiac ECM of the zebrafish
heart tube exhibits regionalized expansion prior to onset of heart tube
morphogenesis, with a thicker ECM in both the left side and future
atrium of the heart tube. Loss-of-function analyses demonstrate that this
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ECM expansion is dependent upon the ECM cross-linking protein
Hyaluronan and Proteoglycan Link Protein 1a (Hapln1a), and that
Hapln1a promotes heart morphogenesis. Finally, we show that while
asymmetric hapln1a expression is independent of laterality cues, the axis
of hapln1a asymmetry in the heart is dictated by embryonic laterality,
supporting a new model where embryonic left–right asymmetry tightly
defines the orientation of ECM asymmetry in the heart tube, and to-
gether these pathways fine tune asymmetric cardiac morphogenesis.
2. Methods
2.1 Zebrafish maintenance
Adult zebrafish were maintained according to standard laboratory condi-
tions. The following lines were used: AB, Tg(myl7:eGFP),20
Tg(myl7:lifeActGFP),21 Tg(fli1a:AC-TagRFP),sh511 22 spawt30973 7,
Tg(lft2BAC:Gal4FF); Tg(UAS;RFP), pkd2hu2173, hapln1aD187 (allele designa-
tion hapln1ash611), hapln1aD241 (allele designation hapln1ash580).
Embryos older than 24hpf were treated with 0.2mM 1-phenyl-2-thio-
urea (PTU) in E3 medium to inhibit melanin production. All animals
were euthanized by immersion in overdose of Tricaine methanesulfo-
nate (1.33 g/L). Animal work was approved by the local Animal Welfare
and Ethical Review Body (AWERB) at the University of Sheffield, con-
ducted in accordance with UK Home Office Regulations under PPLs 70/
8588 and PA1C7120E, and in line with the guidelines from Directive
2010/63/EU of the European Parliament on the protection of animals
used for scientific purposes.
2.2 Generation of hapln1a mutants
CRISPR guide RNAs (gRNAs) were designed to target the putative
promoter region of hapln1a (GRCz11: ENSDART00000122966.4, g1:
50-TCGTCTCTCTCTAAGGGGAGGGG-30) and downstream of the
translation start site (g2: 50-GATGATTGCTCTGTTTTCTGTGG-30).
Sequence-specific CRISPR RNAs (crRNA, Merck) were resuspended in
MilliQ water to 21.4lM, and injected with equimolar tracrRNA (Merck)
together with Cas9 protein (NEB M0386T) into 1-cell stage embryos in
a volume of 1nl. CRISPR-Cas9-injected embryos were raised to adult-
hood and individuals transmitting germline promoter deletions
were identified by PCR using the following primers: forward 50-
ACATTTTGCATGCCCTCGAA-30; reverse 50-TGCATCCTGGACCT
TCATTCA-30. Promoter deletions were identified by Sanger sequenc-
ing. F0 founders transmitting a desirable mutation were established as
stable lines at F2. Two hapln1a promoter deletion alleles were recov-
ered: hapln1aD187 and hapln1aD241.
2.3 mRNA in situ hybridization
Embryos were fixed overnight in 4% PFA, and mRNA in situ hybridiza-
tions carried out as previously described.7 Fluorescent in situ hybridiza-
tions were performed using the TSA kit (Perkin-Elmer).23 Primers used
to generate newmRNA in situ probe constructs and information on pub-
lished probes are detailed in Supplementary material online, Methods.
Riboprobes were transcribed from linearized template in the presence
of DIG-11-UTP or Fluorescein-11-UTP (Roche).
2.4 Immunohistochemistry
Embryos were fixed overnight in 4% PFA with 4% sucrose at 4C. For
Hapln1a immunostaining samples were stored overnight in MeOH at
-20C. After rehydration if applicable, embryos were blocked for 1 h at
room temperature in 0.2% PBS-Triton-X (PBS-Tx) with 10% goat serum.
Embryos were incubated overnight at 4C with primary and secondary
antibodies diluted in PBS-Tx/10% goat serum with 1% DMSO. The fol-
lowing commercially available primary antibodies were used: aGFP
(1:1000 Aves lab), aCT3 (1:100, Developmental Studies Hybridoma
Bank), aCdh524 (1:100). A rabbit polyclonal antibody targeting amino
acids 117–134 (DGMNDMTLEVDLEVQGKD) of zebrafish Hapln1a was
designed and produced by Proteintech. Test bleeds were used to deter-
mine cross-reactivity with Hapln1a by comparing protein localization at
26hpf with mRNA in situ hybridization. Subsequently, affinity-purified
Hapln1a antibody was used at 1:100. Fluorophore-conjugated secondary
antibodies (Jackson labs) were used at 1:200.
2.5 Tomo-seq
Hearts were dissected from Tg(myl7: eGFP) zebrafish embryos at 26hpf
and placed into OCT cryofreezing medium (Sakura Finetek). Blue Affy-
gel beads (BioRad) were placed at each end of the heart tube to aid visu-
alization during sectioning, and the hearts were rapidly frozen and stored
at -80C. Hearts were sectioned using a cryostat at 9 nm resolution.
RNA extraction, aRNA synthesis, library preparation, sequencing, and
data analysis were performed as previously described.25,26
2.6 Morpholino-mediated knockdown and
hapln1a overexpression construct
generation and analysis
A morpholino was designed to target the translational start site of
hapln1a (50-AGAGCAAT[CAT]CTTCACGTTTGTTA-30, brackets de-
note hapln1a ATG reverse complement). Morpholinos blocking tp53,27
(Zfin tp53MO-4) and has228 (Zfin has2MO-1) are previously described.
All morpholinos were supplied by GeneTools and diluted to a 1mM
stock. Working concentrations were as follows: hapln1a 500nM or
250 nM, has2 250 nM, combinatorial has2/hapln1a 250 nM each, tp53
250 nM. has2 and hapln1a morpholinos were co-injected together with
tp53 morpholino. Embryos were injected with 1 nL of morpholino
solution.
The hapln1a coding sequence was amplified using the following
primers containing AttB sequences for Gateway cloning and a Kozak se-
quence (underlined): forward: 50ggggacaagtttgtacaaaaaagcaggctTCG
CCGCCACCATGATTGCTCTGTTTTCTGT 30; reverse: 50GGGGA
CCACTTTGTACAAGAAAGCTGGGTTTTACTGCTGGGCTTTGT
AGCAATA-30. The resulting PCR product was ligated into the pDON
R221 middle entry Gateway vector, generating a pMEhapln1aCDS vec-
tor. Full-length hapln1a was subsequently recombined with a p5E myl7
promoter sequence,29 and a p3E polyA sequence into the
pDestTol2pA3 destination vector30 to generate the pDestmyl7: hapln1a
construct. Gateway cloning was performed using the Tol2kit via stan-
dard protocols.30 60pg of pDestmyl7: hapln1a was co-injected with
25pg of tol2 mRNA into the cell of 1-cell stage embryos. Analysis of
hapln1a overexpression and cardiac morphogenesis was performed us-
ing double in situ hybridization to assess hapln1a andmyl7 expression.
2.7 RNA injections
ssNcan-GFPmRNA was synthesized from the ssNcan-GFP plasmid as pre-
viously described.31 Embryos were injected with 100pg of mRNA in
1 nL volume at the 1-cell stage and screened for GFP at 24hpf.
2.8 Imaging and image quantification
Live zebrafish embryos were imaged on a ZEISS Lightsheet Z.1 micro-
scope. To assess cardiac morphology at 50hpf and 72hpf embryos were













































































































































































































































































anesthetized by immersion in 8.4% Tricaine (Merck 10521) before
mounting in 1% low melting point agarose in E3 with 8.4% Tricaine. To
stop the heart the imaging chamber was filled with E3 with 8.4% Tricaine
and the temperature maintained at 10C. All samples were imaged using
a 20 lens and 1.0 zoom at 0.47–0.65mm z-step size, with sufficient z sli-
ces to capture the entire heart. Dual side lasers with dual side fusion and
pivot scan were used for sample illumination.
Embryos injected with ssNcan-GFP mRNA were fixed overnight in 4%
PFA with 4% sucrose, and the GFP signal amplified by immunohisto-
chemistry. Dissected embryos were imaged using a Zeiss Airyscan mi-
croscope, z stacks were obtained with a step size of 1mm.
Detailed image quantification methodology is included in
Supplementary material online.
3. Results
3.1 The cardiac ECM is asymmetrically
expanded at early stages of heart looping
morphogenesis
During cardiac development the myocardial and endocardial layers of
the heart are separated by the cardiac ECM. We hypothesized there
may be regional differences in the ECM of the zebrafish heart tube which
could promote local changes in tissue shape to drive cardiac morpho-
genesis. To examine regional ECM thickness in the heart tube, we used
live in vivo light-sheet microscopy to image quadruple transgenic zebra-
fish embryos at 26 h post-fertilization (hpf).
Tg(myl7:lifeActGFP); Tg(fli1a:AC-TagRFP); Tg(lft2BAC:Gal4FF); Tg(UAS:RFP)
zebrafish express actin-tagged GFP in the myocardium21 and actin-
localized RFP in the endothelium including the endocardium,22 allowing
visualization of the two tissue layers in the heart tube. The
Tg(lft2BAC:Gal4FF); Tg(UAS:RFP) double transgenic drives RFP in lefty2-
expressing cells, comprising the dorsal myocardium of the heart tube at
26hpf (Figure 1A and Supplementary material online, Figure S1).18,32 This
combination of transgenes allowed imaging of optical cross-sections
through the heart tube at 26hpf, just before the onset of looping mor-
phogenesis, and enabled dorsal–ventral axis orientation of the heart
tube (Figure 1A–G and Supplementary material online, Movie S1). We
consistently observed an asymmetry in the extracellular space between
the myocardial and endocardial layers of the heart in the future atrium,
with an apparent thickening of the ECMon the left side of the tube which
is maintained throughout the cardiac cycle (Figure 1D and G). We quanti-
fied the extracellular space between the two tissue layers and calculated
the ECM left: right ratio (left ECM thickness divided by right ECM thick-
ness, where >1 indicates a left sided expansion). Using this method, we
detected a reproducible expansion of the ECM in the left side of the
heart tube (Figure 1H) which is maintained in the atrium at 50hpf
(Supplementary material online, Figure S2).
Due to technical limitations in imaging deeper cardiac tissue with suffi-
cient resolution at 26hpf, we could only image the superficially located
venous pole/atrium of the heart tube in live embryos. Therefore, to de-
termine whether ECM left–right asymmetry is restricted to the venous
pole or is maintained along the atrioventricular axis of the heart, we per-
formed fixed tissue imaging. Previous studies have demonstrated that hy-
aluronic acid (HA) is present in the cardiac jelly during vertebrate heart
development.17,33,34 To visualize the HA-rich ECM, wild-type embryos
were injected with the HA sensor ssNcan-GFP31 at the 1-cell stage, fixed
at 26hpf, and the GFP signal detected by immunohistochemistry before
imaging the entire heart tube as a z-stack using confocal microscopy
(Figure 1I–K). Optical reslicing of z-stacks generated cross-sections of the
heart tube from the venous pole to the arterial pole, allowing us to quan-
tify the width of the ssNcan-GFP-positive ECM on left and right sides of
the tube along the entire pole-to-pole length of the heart (Figure 1L–N).
We confirmed that the ECM is thicker on the left side of the heart tube
compared to the right, however this asymmetry is more profound at the
venous pole/future atrium than at the arterial pole/future ventricle
(Figure 1N and O). Furthermore, the cardiac ECM is thicker in the future
atrium when compared to the ventricle (Figure 1L–N). Together these
data demonstrate that the heart tube exhibits a regionally expanded
ECM prior to onset of looping morphogenesis.
3.2 hapln1a exhibits regionalized cardiac
expression prior to heart tube formation
and looping morphogenesis
The asymmetric expansion of the cardiac ECM could be due to regional-
ized synthesis of ECM components. However, we did not observe any
clear asymmetry in levels of HA deposition in the cardiac ECM in either
live embryos injected with the ssNcan-GFP sensor (Supplementary mate-
rial online, Figure S3) or in fixed hearts (Figure 1I–K). We also did not find
left–right asymmetry in the heart tube in the expression of hyaluronan
synthase 2 (has2, the major HA producing enzyme), chondroitin sulfate syn-
thase 1 (chsy1), or the ECM proteoglycans versican (vcana/b), aggrecan
(acana/b), all of which have previously been implicated in heart develop-
ment11,17–19,35,36 (Supplementary material online, Figure S3), suggesting
that regionalized synthesis of these proteins is not responsible for ECM
asymmetry. We therefore hypothesized that a protein required for HA
modification or cross-linking may be regionally expressed in the heart
tube.
To identify candidate genes which modulate cardiac ECM expansion,
we took a genome-wide unbiased approach to identify genes expressed
in the heart tube at 26hpf, prior to the onset of looping morphogenesis.
Since we observed the strongest left-sided ECM expansion in the puta-
tive atrium, as well as a generally more expanded ECM at the venous
pole of the heart compared to the arterial pole, we used the previously
described Tomo-seq technique to generate a regionalized map of gene
expression from pole-to-pole in the heart tube25,26 (Figure 2A). We sec-
tioned two individual hearts along the atrioventricular axis, identifying
6787 and 8916 expressed genes (Supplementary material online, Tables
S2–S5), of which approximately half were expressed in more than one
section. By identifying which sections express the atrial marker myh6
(myosin, heavy chain 6, cardiac muscle, alpha), we defined a subset of sec-
tions with atrial identity. We subsequently filtered genes that were up-
regulated in atrial sections compared to ventricular sections in both
hearts and examined this list for genes implicated in ECMmodification.
Using this approach, we identified hyaluronan and proteoglycan link pro-
tein 1a (hapln1a, formerly crtl1) as a candidate to drive regionalized ECM
expansion (Figure 2B). The Hapln family of proteins are secreted into the
ECM where they cross-link HA to proteoglycans,37 suggesting Hapln1a
may modify the cardiac ECM environment. mRNA in situ hybridization
analysis revealed that hapln1a is expressed in the posterior of the heart
disc and cardiac cone prior to formation of the linear heart tube
(Figure 2C and D). At 26hpf, hapln1a expression is up-regulated on the
left side of the heart tube with elevated levels of expression in the future
atrium compared to the future ventricle, recapitulating the regionalized
ECM expansion in the heart (compare Figures 2E and 1K). This dynamic
hapln1a expression is in line with recent studies demonstrating that the


























































































Figure 1 The hyaluronan-rich ECM is asymmetric during early zebrafish heart development. (A) Schematic depicting the developmental stage and orienta-
tion of zebrafish embryos used in live imaging experiments. Optical transverse sections of the heart tube are imaged at the position of the dotted line/dotted
square. Green, myocardium; magenta, endocardium; light pink, dorsal myocardium. (B–G) Light-sheet optical cross-sections through the heart tube of a
26hpf Tg(myl7:lifeActGFP); Tg(fli1a:AC-TagRFP); Tg(lft2BAC:Gal4FF); Tg(UAS:RFP) transgenic embryo during diastole (B–D) and systole (E–G) at the level of the
dotted line in (A). The myocardium is marked in green (B, D, E, and G), and the dorsal myocardium and endocardium are marked in magenta (C, D, F, and G).
The extracellular space between myocardium and endocardium is expanded on the left side of the heart tube (white arrowhead). Scale bar= 50lm. (H)
Quantification of left–right ECM ratio in heart tubes, >1 (red dotted line) denotes left-sided expansion. Mean± SD are plotted, n=6. (I–K) Single confocal z-
planes longitudinally through the heart at 26hpf of embryos injected with ssNcan-GFP (green), counterstained with cardiac troponin (magenta, I, K) and VE-
Cadherin (cyan J, K). (L andM) Transverse optical reslice through the heart tube the venous pole (L) or arterial pole (M). ECM width is measured using the
ssNcan-GFP signal (yellow line) on left and right sides of the tube. (N) Quantification of ECM width on the left (blue) and right (orange) sides of the heart
tube from venous pole to arterial pole at 26hpf. Mean± SD are plotted, n=7. (O) Left–right ECM ratio in the heart tube from venous pole to arterial pole,
where >1 (red dotted line) indicates a left-sided expansion. Mean± SEM are plotted, n=7. The mean L/R ratio across the heart is 1.667, and analysis using a
one-sample t-test shows this significantly differs from 1, P<0.0001 L, left; R, right; VP, venous pole; AP, arterial pole. Scale bar= 50lm.


























































































Figure 2 hapln1a is regionally expressed in the heart tube and secreted asymmetrically into the cardiac jelly. (A) Schematic representation of Tomo-seq
pipeline. GFP-expressing hearts are manually excised from embryos at 26hpf, and frozen in tissue freezing medium. Heart tubes are sectioned along the
atrioventricular axis. RNA extracted from individual slices is labelled with a slice-specific molecular barcode during reverse transcription before generating
sequencing libraries. (B) Example Tomo-seq traces from a single 26hpf heart tube, with individual slices from venous pole to arterial pole along the x-axis
and normalized read number along the y-axis. Read numbers for atrial marker myh6 (green) and ventricular marker myh7 (blue) allows identification of
chamber position within the dataset. hapln1a expression (magenta) is up-regulated in atrial sections. (C–F) mRNA in situ hybridization analysis of hapln1a ex-
pression in the heart between 19hpf and 50hpf. At cardiac disc stage, hapln1a is up-regulated in the posterior (arrow C), which is maintained as the heart
forms the cardiac cone prior to tube formation (arrow D), with lower expression in the anterior cone. Once the heart cone has extended to form the tube,
the previously posterior hapln1a expression is positioned on the left side of the tube (bracket, E), and expressed at higher levels in the atrium (A) than the
ventricle (V). By 50hpf hapln1a expression in the heart is restricted to low levels in the atrioventricular canal (AVC, asterisk, F). Schematics above in situ pan-
els indicate heart morphology at each stage, and hapln1a expression domain within the heart (blue) V, Ventricle; A, Atrium. Scale bar= 100lm. (G–I)
Fluorescent in situ hybridization analysis of hapln1a (magenta) in Tg(myl7:lifeActGFP) transgenic embryos shows hapln1a is expressed in myocardial cells at
26hpf. (J–L) Fluorescent immunostaining of Hapln1a (magenta) in Tg(myl7:lifeActGFP) transgenic embryos demonstrating the protein is secreted into the ex-
tracellular space predominantly on the left side of the heart tube (magenta) at 26hpf. (G and J) Dorsal views. (H and I, K and L) Transverse views. (M–Q)
Fluorescent immunostaining of Hapln1a (magenta) in Tg(myl7:lifeActGFP) transgenic embryos at 50hpf revealing Hapln1a is maintained in the cardiac ECM as
looping progresses. (M–O) Ventral views. (P andQ) Transverse views. L, left; R, right, scale bar= 50lm













































































































































































































































































posterior compartment of the cardiac disc is re-positioned to the left
side of the heart tube.38 By 50hpf hapln1a expression is restricted to low
levels in the atrioventricular canal (Figure 2F). Fluorescent in situ hybridi-
zation demonstrates hapln1a is expressed in the myocardium
(Figure 2G–I), while analysis of Hapln1a protein localization confirms it is
deposited in the ECM (Figure 2J–L). Despite the absence of hapln1a ex-
pression in the heart at 50hpf (Figure 2F), Hapln1a protein is maintained
in the ECM at 50hpf (Figure 2M–Q), suggesting that the ECM environ-
ment established during early stages prior to heart tube formation is
maintained during heart development and may be important for subse-
quent cardiac morphogenesis.
3.3 Hapln1a is required for heart
morphogenesis and promotes ECM
expansion
To determine whether Hapln1a is required for cardiac morphogenesis,
we used CRISPR-Cas9-mediated genome editing to generate hapln1a
mutants by deleting the putative hapln1a promoter therefore abolishing
hapln1a expression (Supplementary material online, Figure S4). We re-
covered two alleles; a 187-bp deletion (hapln1aD187) and a 241-bp dele-
tion (hapln1aD241) and established both as stable lines at F2. Both alleles
remove the initiating ATG and upstream sequence. To confirm both
deletions removed the hapln1a promoter and abrogated transcription,
hapln1a expression was analyzed at 26hpf in F3 mutant embryos.
Homozygous hapln1a promoter mutants of either allele exhibit a com-
plete loss of hapln1a expression at 26hpf compared to wild-type em-
bryos (Figure 3A–C and Supplementary material online, Figure S4),
demonstrating successful deletion of the hapln1a promoter.While analy-
sis of heart development in hapln1a D241 mutants at 50hpf by in situ hy-
bridization of the pan-cardiac marker myl7 (myosin light chain 7) did not
reveal striking abnormalities in cardiac morphogenesis (Figure 3D–F), we
did observe mild heart malformations and an apparent reduction in atrial
size. To investigate this further, we quantified heart size and chamber
morphology at 50hpf by in situ hybridization analysis of myl7, the atrial
marker myh6 and the ventricular marker myh7l (myosin heavy chain 7-
like)39 (Figure 3 and Supplementary material online, Figures S4 and S5).
We observed a reduction in atrial size in hapln1aD241 mutants and a re-
duction in the length of the outer curvature of the atrium in both
hapln1aD241 and hapln1aD187mutants, suggesting a defect in atrial growth
(Figure 3J and K). We performed similar analyses by generating z-projec-
tions of live light-sheet images of Tg(myl7:lifeActGFP); Tg(fli1a:AC-TagRFP)
transgenic wild-type sibling and hapln1a mutant hearts at 50hpf and
72hpf, allowing us to assess ongoing heart morphogenesis without cham-
ber morphology being altered during fixation and processing (Figure 3L–
O and Supplementary material online, Figure S6). We confirmed a reduc-
tion in atrial size and ballooning of the atrial outer curvature in live
hapln1aD241 mutants at 50hpf (Figure 3P and Q), as well as reductions in
atrial perimeter and elongation at 72hpf in hapln1aD187 mutants
(Supplementary material online, Figure S6), with similar trends in reduc-
tion in all atrial parameters across alleles. At 72hpf hapln1a mutants also
display abnormally positioned atria compared to wild-type siblings, with
reduced compaction of the heart, and mispositioning of the atrium and
ventricle relative to each other (Supplementary material online, Figure
S6). While expressivity of phenotype appears variable between alleles,
both exhibit significant changes in morphological parameters indicative
of defective atrial growth. Supporting a requirement in atrial growth spe-
cifically after heart tube formation, we did not observe significant defects
in heart size or tube position at 26hpf, or in looping morphology, or
ventricular growth at 50hpf in hapln1a mutants (Supplementary material
online, Figure S5). Both hapln1amutant alleles are adult viable and we did
not observe more profound defects in maternal-zygotic hapln1amutants
(data not shown). Together this demonstrates that similar to mouse,15
hapln1a is required for atrial morphogenesis in zebrafish.
Hapln1 functions as an ECM binding protein and its localization reca-
pitulates the regionalized ECM expansion in the heart tube, therefore,
we hypothesized that Hapln1a promotes cardiac morphogenesis by driv-
ing regionalized ECM expansion in the heart. Since both hapln1a pro-
moter deletion alleles carry the Tg(myl7:lifeActGFP) transgene, this
prevented analysis of ECM width throughout the heart tube of hapln1a
mutants using the ssNcan-GFP HA sensor. We instead injected a mor-
pholino (MO) against hapln1a into zebrafish embryos at the 1-cell stage
together with a tp53 MO control and the ssNcan-GFP HA sensor and
assessed ECM expansion in the heart tube at 26hpf. Analysis of Hapln1a
protein levels in hapln1a morphants confirms successful blocking of
Hapln1a translation in the morphants (Supplementary material online,
Figure S7). Control embryos injected with tp53MO demonstrate the re-
gionalized ECM expansion previously observed, with a left-sided expan-
sion of the ECM (Figure 4A and B), and a higher level of ECM expansion in
the atrium vs. the ventricle (Figure 4C), although overall ECM width was
slightly reduced compared to uninjected embryos (compare Figures 4C
and 1N). Embryos injected with hapln1a MOþ tp53MO did not exhibit
either atrial or left-sided ECM expansion (Figure 4A, B, and D), suggesting
that Hapln1a drives regionalized ECM expansion in the heart tube. To
confirm a role for Hapln1a in ECM regionalization, we analyzed ECM
size in a series of optical cross-sections from live light-sheet images of
wild-type and hapln1a mutant Tg(myl7:lifeActGFP); Tg(fli1a:AC-TagRFP)
transgenic embryos, taking sections from the atrioventricular canal
through the atrium towards the venous pole at 50hpf and 72hpf
(Figure 4E–H and Supplementary material online, Figure S8). Analysis of
radial ECM width in the atrium of hapln1a mutants revealed a reduction
in ECM specifically in the outer curvature of the atrium proximal to the
AVC (Figure 4H and Supplementary material online, Figure S8, cross-
sections 2–4), where ECM expansion is most profound in wild-type
hearts and defects in atrial morphology occur in hapln1a mutants
(Figure 3K and Q). Together this supports a role for Hapln1a in regionally
regulating cardiac ECM size to promote normal cardiac morphogenesis.
3.4 Hapln1a and HA interact to drive heart
morphogenesis
Hapln1a is a member of a family of ECM binding proteins which cross-
link HAwith proteoglycans.37 Since hapln1a is transiently expressed dur-
ing early heart development at cardiac disc and early tube stage
(Figure 2), this suggests that the cardiac ECM driving continued morpho-
genesis of the heart is established at early stages of heart development
and requires the interaction of Hapln1a with HA. To interrogate the
temporal requirements for HA in heart looping, we applied the HA syn-
thesis inhibitor 4-methylumbelliferone (4-MU40,41) to embryos prior to
the onset of heart tube formation at 18hpf, and either washed the drug
off at 22hpf, or left the embryos to develop to 48hpf, when we assessed
heart morphology. Inhibiting HA synthesis from cardiac disc stage
(18hpf) until 48hpf often arrested heart development mid-way during
tube formation (Supplementary material online, Figure S9), a more pro-
found phenotype than that observed in has2 zebrafish morphants or
Has2 mouse mutants.17,18 However, inhibition of HA synthesis during
the short time window between cardiac disc (18hpf) and cardiac cone
(22hpf) stage, prior to tube formation, resulted in normal tube formation


























































































Figure 3 Hapln1a promotes atrial growth. (A–C) mRNA in situ hybridization analysis of hapln1a expression at 26hpf in embryos from an incross of
hapln1aD241 heterozygous carriers. Wild-type and heterozygous siblings express hapln1a in the heart (bracket A, B, respectively), whereas hapln1a is absent
in homozygous mutants (arrow C). (D–I) mRNA in situ hybridization expression analysis at 50hpf of myl7 (D–F) and myh6 (G–I) in wild-type siblings (D and
G), hapln1aD241 heterozygous siblings (E and H) or hapln1aD241 homozygous mutant embryos (F and I). Scale bar= 50lm. (J and K) Quantification of atrial
area (J), and atrial outer curvature (K) in ISH-processed sibling embryos (wt/het) and hapln1aD241 or hapln1aD187mutants (mut) at 50hpf. Atrial area is signifi-
cantly reduced in hapln1aD241mutants compared to wild-type siblings (P=0.013), and atrial outer curvature is significantly reduced in both hapln1aD187 and
hapln1aD241 mutants (P=0.033 and P=0.032). In both J and K, n=54 hapln1aD187 wt; 104 hapln1aD187 het; 60 hapln1aD187 mut, 66 hapln1aD241 wt; 116
hapln1aD241 het; 53 hapln1aD241 mut. (L–O) Maximum intensity projections of light-sheet z-stacks of live 50hpf (L and M) and 72hpf (N and O)
Tg(myl7:lifeActGFP); Tg(fli1a:AC-TagRFP) transgenic wild-type (L and N), and hapln1aD241 mutant embryos (M and O). Scale bar= 50lm. (P and Q)
Quantification of atrial area (P), and atrial outer curvature (Q) in live light-sheet z-projections fromwild-type sibling embryos and hapln1aD241 or hapln1aD187
mutants at 50hpf and 72hpf. Atrial area and atrial outer curvature are significantly reduced in hapln1aD241mutants (mut) compared to wild-type siblings (wt/
het) at 50hpf (P=0.0002, and P=0.014). In both (P) and (Q), n=4 hapln1aD187 50hpf wt; 5 hapln1aD187 50hpf mut, 7 hapln1aD241 50hpf wt; 10 hapln1aD241
50hpf mut; 4 hapln1aD187 72hpf wt; 7 hapln1aD187 72hpf mut, 9 hapln1aD241 72hpf wt; 10 hapln1aD241 72hpf mut. Comparative statistics carried out using a
Kruskal–Wallis test with multiple comparisons.


























































































Figure 4 Hapln1a drives regionalized ECM expansion. (A) Quantification of ECM left/right width along the longitudinal axis of the heart at 26hpf in em-
bryos injected with either tp53MO (blue, n=5) or hapln1a MOþ tp53 MO (orange, n=6). Mean± SD are plotted. (B) Average ECM width on the left or
right side of the heart tube in embryos injected with tp53MO (blue, n=5) or hapln1aMOþ tp53MO (orange, n=6). tp53-injected controls display an ex-
panded ECM on the left side of the heart tube compared to the right, (P=0.0003, 2-way ANOVA) whereas embryos injected with hapln1aMOþ tp53MO
have a reduced left ECM size when compared to tp53MO injected (P=0.0004), resulting in loss of left-sided ECM expansion. Mean± SD are plotted. (C and
D) Quantification of ECMwidth on the left and right sides of the heart tube from venous pole to arterial pole at 26hpf in embryos injected with tp53MO (C,
n=5) or hapln1aMOþ tp53MO (D, n=6). Mean± SD are plotted. The cardiac ECM in tp53morphants exhibits atrial and left side expansion, whereas the
ECM in hapln1amorphants is more uniform in width from atrium to ventricle and is not expanded on the left side. Mean± SD are plotted. (E) Maximum in-
tensity projection of light-sheet z-stacks of 50hpf Tg(myl7:lifeActGFP); Tg(fli1a:AC-TagRFP) transgenic embryo. Dashed cyan line indicates position of optical
cross-sections. (F) Example orthogonal view through the atrium of wild-type embryo in (E). Blue dashed lines indicate radial positions for measuring ECM
thickness (yellow lines). Scale bar = 50lm. (G) Schematic of radial plot corresponding to radial ECM positions in (F). (H) Quantification of ECMwidth in atrial
cross-sections at defined angular positions along the longitudinal axis of the atrium fromAVC (cross-section 2) towards the venous pole (cross-section 8) at
50hpf in wild-type (blue) or hapln1aD241mutants (orange). Asymmetric ECMwidth is reduced in the outer curvature close to the AVC (cross-sections 2–4)
in hapln1aD241mutants compared to wild-type siblings. Mean± SD are plotted, radial-axis is consistent between plots, n>_ 4 at each location.













































































































































































































































































but a specific disruption to subsequent cardiac looping morphogenesis
(Supplementary material online, Figure S9). This supports the hypothesis
that HA synthesized prior to formation of the heart tube is required for
ongoing morphogenesis of the heart.
Having demonstrated a requirement for HA synthesis in heart mor-
phogenesis during early cardiac development when hapln1a expression
is initiated, we wanted to confirm the interaction of hapln1a and HA in
heart looping morphogenesis. Injection of sub-phenotypic doses of mor-
pholinos targeting either has2 or hapln1a did not result in significant
defects in cardiac morphology at 48hpf (Supplementary material online,
Figure S9). However, co-injection of both has2 and hapln1a morpholinos
results in profound defects in heart development at 48hpf
(Supplementary material online, Figure S9), including a reduction in heart
looping ratio, and abnormal atrial morphology. This is a more severe
phenotype than that observed by either injection of hapln1aMOþ tp53
MO, has2 MOþ tp53 MO, 4MU treatment or deletion of the hapln1a
promoter, suggesting that while timely HA synthesis drives heart mor-
phogenesis subsequent to tube formation, hapln1a is an important re-
gional modulator of this process.
3.5 Hapln1a misexpression results in
abnormal heart morphogenesis
While analysis of hapln1a mutants demonstrates a requirement for
Hapln1a in heart development (Figure 3 and Supplementary material on-
line, Figure S6), we wished to investigate whether the regionalization of
hapln1a expression is important for cardiac morphogenesis. We gener-
ated a DNA construct in which the full-length hapln1a coding sequence
is driven by the pan-myocardialmyl7 promoter, flanked by Tol2 transpo-
son sites to allow integration into the genome (Figure 5A). We co-
injected myl7: hapln1a DNA with tol2 transposase mRNA at the 1-cell
stage and analyzed both myl7 and hapln1a expression at 55hpf, allowing
us to visualize heart morphology alongside assessing the extent of
hapln1amisexpression (Figure 5B–G). We analyzed heart morphology by
quantifying looping ratio and assessed this as a function of percentage
coverage of hapln1a expression in the whole heart (Figure 5H).
Increasing the domain of hapln1a expression in the heart results in a re-
duction in looping morphogenesis (Figure 5H), suggesting that regional-
ized expression of hapln1a in the heart is important for cardiac
morphogenesis. Since hapln1a expression and ECM asymmetry is
greater in the atrium than the ventricle, we hypothesized that hapln1a
misexpression in each chamber may impact differently on heart morpho-
genesis. We quantified hapln1amisexpression in each chamber by calcu-
lating the percentage of the chamber which expresses hapln1a
(Figure 5I–M), and found that while misexpression of hapln1a in the ven-
tricle did not impact upon heart morphogenesis, misexpression of
hapln1a in the atrium decreased looping ratio (Figure 5N). Conversely,
we did not find significant changes in chamber area upon hapln1a overex-
pression (Figure 5O). Together with our observations of abnormal heart
morphology in hapln1a mutants this suggests that spatially restricted
hapln1a expression in the atrium drives cardiac morphogenesis.
3.6 Embryonic left–right asymmetry
orients the axis of ECM asymmetry in the
heart tube
Finally, since hapln1a is asymmetrically expressed on the left side of the
heart tube, and is required for heart morphogenesis, we hypothesized
that it may contribute to a previously-described tissue-intrinsic mecha-
nism of heart looping morphogenesis7 and thus is expressed
independent of embryonic left–right asymmetry cues. Embryos with
mutations in pkd2 (polycystic kidney disease 2), which is required for
Kupffer’s Vesicle function,42 exhibit defects in left–right asymmetry in-
cluding a disruption to normal leftward displacement of the heart tube,42
while spaw mutants lack asymmetric Nodal expression prior to asym-
metric organ morphogenesis resulting in midline positioning of the heart
tube.7 We hypothesized that induction of hapln1a expression occurs in-
dependent of embryonic laterality cues, but that asymmetric positioning
of hapln1a-expressing cells in the heart tube may be tightly linked to the
direction of heart tube position, and therefore dictated by embryonic
left–right asymmetry. We analyzed hapln1a expression in an incross of
pkd2hu2173 and spaw heterozygotes and found that consistent with our
hypothesis hapln1a is always expressed in the posterior of the heart disc
in both pkd2hu2173 mutants and spaw mutants at 19hpf (Figure 6A–D).
Importantly, at 26hpf, we observed that positioning of hapln1a-express-
ing cells is dependent upon cardiac position—in pkd2hu2173 mutants
where the heart is positioned to the right, hapln1a is up-regulated on the
right side of the tube, whereas if the heart remains midline, hapln1a does
not exhibit a clear left–right asymmetry in up-regulation (Figure 6E–H).
Similarly, analysis of Hapln1a deposition in spawmutants at 26hpf reveals
Hapln1a is no longer positioned on the left side of the heart tube, but in-
stead is secreted into the cardiac ECM on the ventral face of the heart
(Figure 6I–P). These data support a model where laterality cues do not
initiate hapln1a expression but are required for its subsequent position
in the heart tube.
Together, this supports a model where initiation of hapln1a expres-
sion in the posterior cardiac disc is independent of laterality cues, but the
subsequent cell movements which occur during heart tube formation re-
position this population of cells to the left side of the heart, dictating the
axis of ECM asymmetry in the heart tube.
4. Discussion
The process of forming the complex heart from a simple linear tube
requires careful coordination of spatially restricted extrinsic signals and
highly regionalized changes in cell shape and tissue growth to ensure cor-
rect shaping of the developing tissue. Our data show that the zebrafish
heart tube exhibits regionalized ECM expansion that is dependent upon
localized expression of the ECM binding protein hapln1a and this pro-
motes cardiac morphogenesis. Our finding that while the onset of
hapln1a in the posterior cardiac disc is independent of embryonic left–
right asymmetry, laterality cues are required to orient asymmetric
Hapln1a deposition along the left–right axis of the heart tube, allows us
to propose a new model in which heart-extrinsic embryonic asymmetry
orients tissue-intrinsic cardiac ECM asymmetry, ensuring that direction-
ality and growth of the heart are tightly coordinated to fine tune cardiac
morphogenesis (Figure 7).
Interestingly, the only other gene thus far identified specifically in the
posterior cardiac disc/left heart tube in zebrafish is meis2b.38 meis2b
mutants exhibit defects in atrial morphology at juvenile and adult stages,
supporting our conclusion that early anterior–posterior asymmetry in
the heart disc/left–right asymmetry in the heart tube are important for
continual cardiac morphogenesis. However, contrary to our study which
reveals a reduced atrial size in hapln1a mutants, meis2b mutant adult
zebrafish exhibit an enlarged atrium,38 suggesting these two genes play
opposing roles in atrial morphogenesis. Investigating hapln1a expression
in meis2b mutants may uncover any interactions between these two
genes in heart development. Similarly, hapln1a mutants are adult viable,


























































































Figure 5 Regionalized hapln1a expression in the atrium promotes heart morphogenesis. (A) Schematic of DNA construct used to misexpress hapln1a
specifically in cardiomyocytes. (B–G) Example images of heart morphology (myl7, red) upon different levels of hapln1amisexpression (blue) at 55hpf, related
to the quantification method depicted in (I–M). Percentage indicates hapln1a coverage of the atrium. (H) Scatter plot depicting looping ratio as a function of
percentage of the heart covered by hapln1a expression together with linear regression of the data (n=174). Spearman’s correlation coefficient (r) deviates
significantly from zero (P<0.0001) demonstrating that increased coverage of hapln1a in the myocardium results in reduced heart looping morphogenesis.
Red dashed box indicates embryos with wild-type levels of hapln1a expression. (I–M) Quantification approach to analyze pan-cardiac or chamber-specific
hapln1a misexpression at 55hpf. The number of hapln1a-positive pixels within each chamber is measured alongside the total chamber area, quantifying the
percentage of the chamber expressing hapln1a. (N–O) Analysis of looping ratio (N) and chamber area (O) as a function of the level of hapln1a expression in
each chamber of the heart. Embryos are categorized depending on the percentage of the chamber expressing hapln1a. Misexpression of hapln1a in the ven-
tricle does not affect looping ratio, whereas misexpression of hapln1a in the atrium significantly reduces looping ratio at >_30% coverage (N). hapln1amisex-
pression in either chamber does not appear to alter overall heart size (O). ns= not significant. In both (N) and (O), atrium misexpression categories: n=92
(0–10%); 43 (10–20%); 17 (20–30%); 12 (30–40%); 9 (40þ%); ventricle misexpression categories: n=73 (0–10%); 41 (10–20%); 25 (20–30%); 12 (30–40%);
23 (40þ%). Comparative statistics carried out using a Kruskal–Wallis test with multiple comparisons.





































































































































and comparing atrial phenotypes in juveniles and adults will better define
the phenotypic relationship between these two genes, as well as the im-
pact of abnormal embryonic morphology on adult heart form and func-
tion. Furthermore, recent studies have shown that cross-talk between
the myocardium and endocardium modulates atrial growth,43 and our
study suggests that differential ECM composition and/or degradation
may help regionally fine tune this process to dictate chamber
morphology.
The mechanism by which regionalized ECM composition modulates
cardiac morphogenesis remains unclear. A major role of the ECM in tis-
sue morphogenesis is to provide structural or biomechanical cues to
neighbouring tissues. Alternatively, Hapln1a-mediated cross-linking may
modulate regional stiffness of the cardiac ECM, and differential matrix
stiffness has been shown to regulate cardiomyocyte form and
function.44–47 Importantly, we do not see defects in heart rate in hapln1a
mutants (Supplementary material online, Figure S5), suggesting this re-
gionalized ECM is not regulating cardiac function. In addition to provision
of mechanical cues to the surrounding cells, the ECM also modulates dif-
fusion and availability of extracellular signalling molecules.48 It is there-
fore tempting to speculate that the specific ECM environment allows
precise regionalized cellular responses to pan-cardiac or chamber spe-
cific signalling pathways.
Hapln proteins cross-link HA to proteoglycans. HA and Versican have
previously been implicated in heart development, however global loss of
these genes throughout the heart result in profound morphological
defects.17,19 We suggest that regionalized modification of the ECM by
Hapln1a allows the developing heart to generate different regional
responses to globally deposited ECM components, resulting in spatial
Figure 6 Posterior up-regulation of hapln1a in the cardiac disc is independent of left–right asymmetry. (A–G) mRNA in situ hybridization analysis of
hapln1a expression in an incross of spaw (A and B) or pkd2hu2173 (C–G) heterozygous carriers. At 19hpf hapln1a is expressed in the posterior cardiac disc of
both spawmutant embryos (B, n=17/19), and pkd2mutant embryos (D, n=13/13), similar to sibling embryos. At 26hpf pkd2mutant hearts that have jogged
to the left exhibit left side up-regulation of hapln1a (E, n=18), pkd2 mutant hearts on the right have right side up-regulation of hapln1a (F, n=9), and pkd2
mutant hearts that remain at the midline have no clear left–right asymmetry in expression (G, n=13). (H) Quantification of position of hapln1a expression in
sibling and pkd2hu2173 mutant embryos at 26hpf, n=138 pkd2hu2173 siblings, 40 pkd2hu2173 mutants. (I–P) Fluorescent immunostaining of Hapln1a (magenta)
and cardiac troponin (green) at 26hpf in wild-type siblings (I–L) or spawmutant embryos (M–P).Wild-type siblings exhibit left-sided deposition of Hapln1a in
the heart tube (I–L, n=6), whereas spawmutant embryos exhibit ventral localization of Hapln1a (M–P, n=6). (I andM) Dorsal views. (J–L and N–P) Optical
transverse sections. Scale bar= 50lm. L, left; R, right; D, dorsal; V, ventral.




































































































































































fine-tuning of the specific morphological rearrangements required for
complex tissue shaping. While regional ECM cross-linking may change
the biomechanical properties of the ECM by stabilizing these compo-
nents in specific regions of the heart tube, HA and proteoglycan cleavage
products can also act as signalling molecules.49 Our finding that hapln1a
and has2 work synergistically to promote heart morphogenesis suggests
that Hapln1a could promote regional atrial growth by regulating HA sig-
nalling in the heart.
Importantly, while our data show that ECM regionalization appears
to be the result of asymmetric hapln1a expression and deposition,
other factors may support and maintain ECM regionalization during
development. Although we do not observe asymmetric has2 expres-
sion, we cannot rule out asymmetries in deposition which current an-
alytical methods are not sensitive enough to detect. Similarly, we
cannot discard the possibility that asymmetric activity of additional
ECM modifiers or hyaluronidases enhance ECM regionalization
through localized degradation, and there is some evidence that hya-
luronidases themselves are regionally localized in the heart tube.50
This suggests multiple regulatory mechanisms may interact to region-
alize HA/ECM activity in the developing heart. Comparative quantita-
tive analysis of cardiac morphology in single and combinatorial
knockout models will help define how ECM components and modi-
fiers interact to contribute to heart morphogenesis. Our relatively
simplistic analysis of 3D chamber morphology suggests that 2D
analyses do not capture all aspects of cardiac morphology during de-
velopment, and thus defining the links between spatiotemporal ECM
dynamics and cardiac morphology requires better definition of
changes in ECM composition and morphological cardiac parameters
in 3D.
Additionally, Hapln1 mouse mutants exhibit decreased protein levels
of the proteoglycan Versican,15 suggesting that Hapln1-mediated HA-
Versican cross-linking prevents degradation of one or both of these
components. Further supporting an interaction between Hapln1a,
Versican, and HA in heart morphogenesis, both mice and medaka lacking
Versican exhibit severe cardiac malformations.19,36 Versican proteins
can be subject to cleavage by ADAMTS proteases,51 depending on iso-
form and domain structure, and reduction in ADAMTS protease activity
results in reduced Versican cleavage and cardiac abnormalities.52,53 We
have shown that of the two zebrafish versican paralogs, only vcana ex-
pression overlaps the hapln1a expression domain (Supplementary mate-
rial online, Figure S3). Zebrafish Vcana appears to be a small V3 or V4-like
isoform which is not predicted to undergo cleavage (Uniprot ID
A0A2R8Q3K1). This suggests that in zebrafish Hapln1a may not stabilize
Versican in the ECM, and alternatively Hapln1a cross-linking may pro-
mote regional degradation of HA in the heart tube.
Hapln1 mutant mouse embryos also exhibit relatively mild structural
cardiac malformations consistent with abnormal early cardiac morpho-
genesis.15However, while that study describes Hapln1 expression in the
Figure 7 Left–right asymmetry orients ECM asymmetry in the heart tube to fine tune cardiac morphogenesis. Model depicting the interaction between
embryonic laterality and ECM regionalization in cardiac morphogenesis. LPM, lateral plate mesoderm; L, left; R, right.













































































































































































































































































valve leaflets it does not address a potentially conserved role for tran-
siently asymmetric Hapln1 expression during earlier heart development.
Zebrafish have two hapln1 paralogs, each with a distinct expression pro-
file in the heart during development, with hapln1b expressed primarily in
the endocardium (data not shown). Thus, zebrafish provide an opportu-
nity to define tissue-specific requirements for Hapln1 function in either
the myocardium or endocardium during cardiac morphogenesis.
Together this study identifies a novel functional role for ECM regional-
ization in the developing heart, mediated by the HA cross-linking protein
Hapln1a, and provides a new model in which ECM regionalization acts
together with embryonic laterality cues to drive cardiac morphogenesis.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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Translational Perspective
This study reveals that the cardiac ECM exhibits regional specialization required for heart morphogenesis, and sheds light on how embryonic left–
right asymmetry acts in concert with ECM regionalization to fine tune heart shape. This work can help us understand the origins of congenital heart
defects, and in particular the nature of morphological heart abnormalities in patients with heterotaxia-associated heart malformations. Furthermore,
recent studies suggest the ECM is a key regulator of regenerative potential in the heart, thus defining how distinct ECM composition impacts upon
heart form and function has implications for developing regenerative therapies in the future.
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